Compass Therapeutics, Inc. (OTC:CMPX) Forecasted to Post FY2023 Earnings of ($0.48) Per Share

Compass Therapeutics, Inc. (OTC:CMPX – Get Rating) – Research analysts at B. Riley decreased their FY2023 earnings per share (EPS) estimates for shares of Compass Therapeutics in a note issued to investors on Tuesday, May 10th. B. Riley analyst J. Walsh now anticipates that the company will post earnings of ($0.48) per share for the year, down from their prior forecast of ($0.47). B. Riley currently has a “Buy” rating and a $10.00 price objective on the stock. B. Riley also issued estimates for Compass Therapeutics’ FY2025 earnings at ($0.67) EPS.

Several other research firms also recently commented on CMPX. Zacks Investment Research downgraded Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, April 4th. HC Wainwright assumed coverage on Compass Therapeutics in a research note on Friday, January 21st. They set a “buy” rating and a $11.00 price objective for the company. Finally, LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research report on Tuesday, March 15th. They set a “buy” rating and a $7.00 target price on the stock. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $8.91.

CMPX traded up $0.46 on Friday, hitting $2.30. 691,846 shares of the company traded hands, compared to its average volume of 215,752. The company has a 50 day moving average of $1.50 and a 200-day moving average of $2.10. Compass Therapeutics has a 12-month low of $1.25 and a 12-month high of $5.92.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Difesa Capital Management LP bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $33,000. Millennium Management LLC bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $35,000. Mirabella Financial Services LLP bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $60,000. JPMorgan Chase & Co. bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $75,000. Finally, New Capital Management LP acquired a new position in Compass Therapeutics in the fourth quarter worth approximately $77,000. 66.04% of the stock is currently owned by institutional investors.

In other Compass Therapeutics news, Director Orbimed Advisors Llc bought 90,712 shares of the business’s stock in a transaction on Monday, May 9th. The shares were purchased at an average price of $1.56 per share, with a total value of $141,510.72. Following the completion of the acquisition, the director now directly owns 14,601,031 shares of the company’s stock, valued at approximately $22,777,608.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas J. Schuetz purchased 27,836 shares of the business’s stock in a transaction dated Tuesday, May 10th. The shares were acquired at an average cost of $1.80 per share, for a total transaction of $50,104.80. Following the acquisition, the chief executive officer now owns 5,153,303 shares of the company’s stock, valued at approximately $9,275,945.40. The disclosure for this purchase can be found here. Insiders have bought 128,748 shares of company stock valued at $208,242 over the last 90 days.

About Compass Therapeutics (Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.

See Also